日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen.

在移植了非进展者外周血单核细胞的 SCID-Hu 小鼠中,对人类免疫缺陷病毒攻击的复制的抵抗力是由 CD8(+) T 细胞介导的,并且与对 p24 抗原的增殖反应有关

de Quiros J C, Shupert W L, McNeil A C, Gea-Banacloche J C, Flanigan M, Savage A, Martino L, Weiskopf E E, Imamichi H, Zhang Y M, Adelsburger J, Stevens R, Murphy P M, Zimmerman P A, Hallahan C W, Davey R T Jr, Connors M

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients

一项随机、对照的 I/II 期临床试验,研究地拉韦啶 (U-90152S) 与传统核苷类药物联合治疗 1 型人类免疫缺陷病毒感染患者的疗效。

Davey, R T Jr; Chaitt, D G; Reed, G F; Freimuth, W W; Herpin, B R; Metcalf, J A; Eastman, P S; Falloon, J; Kovacs, J A; Polis, M A; Walker, R E; Masur, H; Boyle, J; Coleman, S; Cox, S R; Wathen, L; Daenzer, C L; Lane, H C